Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)
EUR 49.36
(-0.32%)
EUR 49.36
(-0.32%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 38.57 Million EUR | -16.22% |
| 2022 | 46.04 Million EUR | -12.34% |
| 2021 | 52.52 Million EUR | -2.63% |
| 2020 | 53.94 Million EUR | -1.37% |
| 2019 | 54.69 Million EUR | 229.69% |
| 2018 | 16.58 Million EUR | -38.63% |
| 2017 | 27.02 Million EUR | 29.77% |
| 2016 | 20.82 Million EUR | -0.5% |
| 2015 | 20.93 Million EUR | -34.65% |
| 2014 | 32.03 Million EUR | 41.87% |
| 2013 | 22.57 Million EUR | -22.51% |
| 2012 | 29.13 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 59.62 Million EUR | 54.58% |
| 2024 Q2 | 80.68 Million EUR | 35.32% |
| 2023 FY | 38.57 Million EUR | -16.22% |
| 2023 Q2 | 54.54 Million EUR | -4.11% |
| 2023 Q1 | 56.87 Million EUR | 23.53% |
| 2023 Q3 | 52.07 Million EUR | -4.52% |
| 2023 Q4 | 38.57 Million EUR | -25.93% |
| 2022 Q2 | 66.37 Million EUR | 0.47% |
| 2022 FY | 46.04 Million EUR | -12.34% |
| 2022 Q4 | 46.04 Million EUR | -31.08% |
| 2022 Q3 | 66.8 Million EUR | 0.65% |
| 2022 Q1 | 66.06 Million EUR | 25.79% |
| 2021 Q2 | 67.24 Million EUR | -0.2% |
| 2021 Q1 | 67.38 Million EUR | -1.52% |
| 2021 Q4 | 52.52 Million EUR | -21.23% |
| 2021 Q3 | 66.67 Million EUR | -0.85% |
| 2021 FY | 52.52 Million EUR | -2.63% |
| 2020 Q4 | 68.42 Million EUR | -0.69% |
| 2020 FY | 53.94 Million EUR | -1.37% |
| 2020 Q3 | 68.89 Million EUR | -0.99% |
| 2020 Q2 | 69.58 Million EUR | -2.29% |
| 2020 Q1 | 71.21 Million EUR | -1.23% |
| 2019 Q2 | 34.45 Million EUR | 3.48% |
| 2019 Q4 | 72.1 Million EUR | 115.47% |
| 2019 Q1 | 33.29 Million EUR | 100.74% |
| 2019 FY | 54.69 Million EUR | 229.69% |
| 2019 Q3 | 33.46 Million EUR | -2.89% |
| 2018 Q1 | 22.28 Million EUR | -17.55% |
| 2018 Q3 | 20.64 Million EUR | 6.45% |
| 2018 Q2 | 19.38 Million EUR | -13.0% |
| 2018 FY | 16.58 Million EUR | -38.63% |
| 2018 Q4 | 16.58 Million EUR | -19.63% |
| 2017 Q4 | 27.02 Million EUR | -17.6% |
| 2017 FY | 27.02 Million EUR | 29.77% |
| 2017 Q3 | 32.8 Million EUR | -9.17% |
| 2017 Q2 | 36.11 Million EUR | -5.71% |
| 2017 Q1 | 38.29 Million EUR | 83.88% |
| 2016 FY | 20.82 Million EUR | -0.5% |
| 2016 Q3 | 24.27 Million EUR | -10.26% |
| 2016 Q2 | 27.05 Million EUR | -9.72% |
| 2016 Q1 | 29.96 Million EUR | -8.18% |
| 2016 Q4 | 20.82 Million EUR | -14.2% |
| 2015 Q1 | 30.99 Million EUR | -3.25% |
| 2015 FY | 20.93 Million EUR | -34.65% |
| 2015 Q4 | 32.63 Million EUR | -9.12% |
| 2015 Q3 | 35.9 Million EUR | 22.99% |
| 2015 Q2 | 29.19 Million EUR | -5.8% |
| 2014 Q2 | 20.92 Million EUR | -2.71% |
| 2014 Q1 | 21.51 Million EUR | -4.73% |
| 2014 FY | 32.03 Million EUR | 41.87% |
| 2014 Q4 | 32.03 Million EUR | -2.59% |
| 2014 Q3 | 32.88 Million EUR | 57.13% |
| 2013 Q3 | 22.9 Million EUR | -3.15% |
| 2013 FY | 22.57 Million EUR | -22.51% |
| 2013 Q4 | 22.57 Million EUR | -1.41% |
| 2013 Q1 | 28.74 Million EUR | -1.32% |
| 2013 Q2 | 23.64 Million EUR | -17.74% |
| 2012 Q4 | 29.13 Million EUR | 0.0% |
| 2012 FY | 29.13 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Boiron SA | 6.64 Million EUR | -480.512% |
| Vetoquinol SA | 9.66 Million EUR | -299.203% |
| Valneva SE | 132.76 Million EUR | 70.946% |
| AB Science S.A. | 16.98 Million EUR | -127.072% |
| Nanobiotix S.A. | 41.66 Million EUR | 7.405% |
| PHAXIAM Therapeutics S.A. | 7.03 Million EUR | -448.72% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |
| BioSenic S.A. | 15.57 Million EUR | -147.704% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 13.697% |
| Formycon AG | 7.81 Million EUR | -393.602% |